Ivermectin for Malaria Vector Control: Mechanisms and Clinical Evidence

Ivermectin kills Anopheles mosquitoes feeding on treated hosts and is being evaluated as a complementary malaria vector control tool. This narrative review synthesizes evidence regarding glutamate-gated chloride channels (GluCl), mosquito-lethal human metabolites, effects on Plasmodium sporogony, and clinical trial outcomes. A structured PubMed search identified mechanistic, entomological, pharmacokinetic, and clinical studies published primarily between 2016 and 2026. Laboratory studies demonstrate biological plausibility, showing mosquito mortality and impaired sporogony. Human metabolites also contribute significantly to mosquitocidal activity. However, population-level evidence remains inconsistent. While a Kenyan trial demonstrated reduced malaria infection incidence, the Mozambique BOHEMIA trial faced operational disruptions, and RIMDAMAL II in Burkina Faso showed no significant incidence reduction when combined with seasonal malaria chemoprevention. Furthermore, a 2026 meta-analysis confirmed stronger evidence for mosquito mortality than for consistent epidemiological benefits. Thus, ivermectin is a promising investigational adjunct rather than a replacement for core interventions. Future research must standardize endpoints, optimize dosing, and evaluate context-specific effectiveness.

Authors

Institutions

Publication Details

Journal
Health & Medical Sciences
Published
2026-11-18
DOI
https://doi.org/10.47134/phms.v4i1.810
Primary Topic
Malaria Research and Control
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ivermectin for Malaria Vector Control: Mechanisms and Clinical Evidence

Mike Permata Sari, Afifa Radhina, Nurul Ain
1 links
Health & Medical Sciences
Malaria Research and Control
article

Ivermectin for Malaria Vector Control: Mechanisms and Clinical Evidence

Mike Permata Sari, Afifa Radhina, Nurul Ain
article en

Abstract

Ivermectin kills Anopheles mosquitoes feeding on treated hosts and is being evaluated as a complementary malaria vector control tool. This narrative review synthesizes evidence regarding glutamate-gated chloride channels (GluCl), mosquito-lethal human metabolites, effects on Plasmodium sporogony, and clinical trial outcomes. A structured PubMed search identified mechanistic, entomological, pharmacokinetic, and clinical studies published primarily between 2016 and 2026. Laboratory studies demonstrate biological plausibility, showing mosquito mortality and impaired sporogony. Human metabolites also contribute significantly to mosquitocidal activity. However, population-level evidence remains inconsistent. While a Kenyan trial demonstrated reduced malaria infection incidence, the Mozambique BOHEMIA trial faced operational disruptions, and RIMDAMAL II in Burkina Faso showed no significant incidence reduction when combined with seasonal malaria chemoprevention. Furthermore, a 2026 meta-analysis confirmed stronger evidence for mosquito mortality than for consistent epidemiological benefits. Thus, ivermectin is a promising investigational adjunct rather than a replacement for core interventions. Future research must standardize endpoints, optimize dosing, and evaluate context-specific effectiveness.

Health & Medical SciencesVol. 4(1)
Syarif Hidayatullah State Islamic University Jakarta (ID), Universitas Pembangunan Nasional Veteran Jakarta (ID), Institut Kesehatan Hermina (ID)
Good health and well-being
Malaria Research and Control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon